On Building A Better R&D Machine, Part 1: Pfizer’s R&D Chief Mikael Dolsten Talks Organizational Structure And Innovation
This article was originally published in The Pink Sheet Daily
Since ascending to the top R&D spot at the world’s largest pharmaceutical company, Mikael Dolsten has taken the lead in focusing R&D at Pfizer and optimizing its portfolio. In Part 1 of a two-part interview with "The Pink Sheet" DAILY, Dolsten shares his thoughts on fine-tuning the R&D organization for speed and efficiency and on whether innovation can be repeated.
You may also be interested in...
Executives presenting at the Barclays Capital Healthcare Conference on March 13-14 discussed everything from early pipeline progress to launch performance.
Pfizer developed crizotinib and its companion diagnostic in just four years after identifying an aberrant ALK gene as the target, spanning a corporate restructuring, the Wyeth integration, and the departure of senior staff in the R&D organization and oncology BU. The next year or so will tell whether Xalkori was a flash in the pan, or whether it marks the long awaited turnaround for Pfizer’s oncology business and a model for nimble drug development.
Pfizer gained the therapy to treat a rare genetic neurologic disorder in its 2010 acquisition of folded protein company FoldRx.